{"entity":{"id":"nct07011654","kind":"trial","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","aka":[],"tldr":"A phase 1/2 trial of sacituzumab govitecan and naxitamab in triple-negative breast cancer, run by M.D. Anderson Cancer Center, now recruiting.","summary":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) is a phase 1/2, interventional study registered as NCT07011654 by M.D. Anderson Cancer Center, with a registry enrolment figure of 31 participants, started 2025-09-19 and due to reach its primary completion in 2028-07-01. Interventions recorded: Sacituzumab govitecan; Naxitamab. Conditions listed: Metastatic Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Histologically confirmed metastatic TNBC\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07011654","url":"https://clinicaltrials.gov/study/NCT07011654"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["sacituzumab-govitecan","naxitamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07011654","phase":"1/2","setting":"Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","sponsor":"M.D. Anderson Cancer Center","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07011654/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}